Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription


2 AJR Am J Roentgenol
1 Am J Gastroenterol
1 Biochem Biophys Res Commun
2 BMC Cancer
2 BMC Gastroenterol
2 Dig Dis Sci
1 Endoscopy
1 Gastroenterology
4 Gut
2 Hepatology
1 J Gastroenterol Hepatol
3 J Hepatol
3 J Pediatr
1 Oncogene
2 PLoS One
1 Radiol Imaging Cancer
1 Radiology
2 Transplant Proc

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. KIM SH, Navot B, Guniganti P, Gavlin A, et al
    Liver Transplant for Non-Hepatocellular Malignancies: A Review for Radiologists.
    AJR Am J Roentgenol. 2022 May 11. doi: 10.2214/AJR.22.27783.
    PubMed         Abstract available

  2. REES MA, Schooler GR, Chavhan GB, Towbin AJ, et al
    Imaging Features of Hepatocellular Carcinoma in Children With and Without Underlying Risk Factors.
    AJR Am J Roentgenol. 2022 May 11. doi: 10.2214/AJR.22.27600.
    PubMed         Abstract available

    Am J Gastroenterol

  3. ACHANTA CR, Kinhal SV, Imandi V, Singh A, et al
    Motorized Spiral Enteroscope Guided Biliary Intervention for Treatment of Biliary Obstruction in Patient with HepaticoJejunostomy.
    Am J Gastroenterol. 2022 May 9. pii: 00000434-990000000-00372.

    Biochem Biophys Res Commun

  4. ZHANG X, An T, Zhang X, Shen T, et al
    DDX17 protects hepatocytes against oleic acid/palmitic acid-induced lipid accumulation.
    Biochem Biophys Res Commun. 2022;612:169-175.
    PubMed         Abstract available

    BMC Cancer

  5. KOBAYASHI S, Fukushima T, Ueno M, Moriya S, et al
    A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
    BMC Cancer. 2022;22:517.
    PubMed         Abstract available

  6. DAI K, Liu C, Guan G, Cai J, et al
    Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
    BMC Cancer. 2022;22:496.
    PubMed         Abstract available

    BMC Gastroenterol

  7. WANG NL, Lin J, Chen L, Lu Y, et al
    Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency.
    BMC Gastroenterol. 2022;22:227.
    PubMed         Abstract available

  8. YOU N, Wu K, Li J, Zheng L, et al
    Laparoscopic liver resection of segment 8 via a hepatic parenchymal transection-first approach guided by the middle hepatic vein.
    BMC Gastroenterol. 2022;22:224.
    PubMed         Abstract available

    Dig Dis Sci

  9. ASOTIBE JC, Banini BA
    Hepatic Hydrothorax: An Independent Predictor of Mortality in Cirrhosis? Is the MELD-Na Score Worth Its Salt?
    Dig Dis Sci. 2022 May 9. pii: 10.1007/s10620-022-07523.

  10. OSMAN KT, Abdelfattah AM, Mahmood SK, Elkhabiry L, et al
    Refractory Hepatic Hydrothorax Is an Independent Predictor of Mortality When Compared to Refractory Ascites.
    Dig Dis Sci. 2022 May 9. pii: 10.1007/s10620-022-07522.
    PubMed         Abstract available


  11. RIVORY J, Pioche M, Dumortier J, Lambin T, et al
    Transesophageal endoscopic ultrasound-guided coil and cyanoacrylate treatment of challenging esophageal varices bleeding associated with CREST syndrome ulcerative esophagitis.
    Endoscopy. 2022 May 6. doi: 10.1055/a-1814-4140.


  12. SINGH SP
    Proton pump inhibitor increasing the risk of infection and mortality in cirrhosis- need closer look!
    Gastroenterology. 2022 May 2. pii: S0016-5085(22)00458.


  13. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022;71:778-788.
    PubMed         Abstract available

  14. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
    Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
    Gut. 2022;71:807-821.
    PubMed         Abstract available

  15. HOHMANN N, Schroder F, Moreira B, Teng H, et al
    Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
    Gut. 2022;71:842-844.

  16. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.


  17. MEHTA S, Asrani SK
    The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
    Hepatology. 2022 May 5. doi: 10.1002/hep.32559.

  18. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.

    J Gastroenterol Hepatol

  19. TENG PC, Agopian VG, Lin TY, You S, et al
    Circulating tumor cells: a step toward precision medicine in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 May 11. doi: 10.1111/jgh.15886.
    PubMed         Abstract available

    J Hepatol

  20. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.

  21. SCHEINER B, Pinter M
    Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.

  22. WANG YZ
    Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.

    J Pediatr

    Autoantibodies in Children with Overweight and Obesity with Nonalcoholic Fatty Liver Disease: the major role of laboratory technique.
    J Pediatr. 2022 Jan 30. pii: S0022-3476(22)00068.

  24. SHLOMOVICH M, Ovchinsky N
    50 Years Ago in TheJournalofPediatrics: Hepatic Encephalopathy: Progress Made, but Mystery Remains.
    J Pediatr. 2022;244:100.

    50 Years Ago in TheJournalofPediatrics: Reye Syndrome: What Was It? Where Did It Go? Will It Come Back?
    J Pediatr. 2022;244:e10.


  26. CHEN S, Cheng J, Zhong Y, Liu R, et al
    Correction: Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells.
    Oncogene. 2022 May 6. pii: 10.1038/s41388-022-02337.

    PLoS One

  27. SAXENA R, Nassiri M, Yin XM, Morral N, et al
    Insights from a high-fat diet fed mouse model with a humanized liver.
    PLoS One. 2022;17:e0268260.
    PubMed         Abstract available

  28. HICKMAN TL, Choi E, Whiteman KR, Muralidharan S, et al
    BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    PLoS One. 2022;17:e0266980.
    PubMed         Abstract available

    Radiol Imaging Cancer

  29. WESDORP NJ, Kemna R, Bolhuis K, van Waesberghe JHTM, et al
    Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases.
    Radiol Imaging Cancer. 2022;4:e210105.
    PubMed         Abstract available


  30. RAMAN AG, Jones C, Weiss CR
    Machine Learning for Hepatocellular Carcinoma Segmentation at MRI: Radiology In Training.
    Radiology. 2022 May 10:212386. doi: 10.1148/radiol.212386.
    PubMed         Abstract available

    Transplant Proc

  31. PERALES SR, Teramoto FD, Ataide EC, Garcia A, et al
    Refinement of the Milan Criteria: Role of alpha-Fetoprotein In Liver Transplantation for Hepatocellular Carcinoma.
    Transplant Proc. 2022 May 7. pii: S0041-1345(22)00282.
    PubMed         Abstract available

  32. DE ATAIDE EC, Perales SR, Teramoto FD, Garcia A, et al
    Validation of Metroticket Score in the Preoperative Period of Liver Transplantation for Hepatocellular Carcinoma.
    Transplant Proc. 2022 May 6. pii: S0041-1345(22)00273.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.